How to access Fasenra from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A patient in Saudi Arabia with severe eosinophilic asthma may receive a prescription for Fasenra (benralizumab) from their treating pulmonologist or allergist. Fasenra is FDA-approved as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients 12 years and older. It is an anti-IL-5 receptor alpha monoclonal antibody manufactured by AstraZeneca that directly depletes eosinophils via antibody-dependent cellular cytotoxicity, a mechanism distinct from anti-IL-5 ligand blockade. In Saudi Arabia, Fasenra is available through some tertiary hospital pharmacies, but for families whose pulmonologists want a specific start date, the pre-filled "autoinjector" presentation, or a documented DSCSA chain-of-custody, the SFDA named-patient import route is a clean alternative.
This guide explains the pathway, documentation your physician prepares, indicative timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Fasenra binds the IL-5 receptor alpha subunit expressed on eosinophils and basophils, triggering antibody-dependent cellular cytotoxicity that near-completely depletes these cells. This distinguishes it from Nucala and Cinqair, which bind the IL-5 ligand itself rather than its receptor. Dosing is 30 mg SC every four weeks for the first three doses, then every eight weeks, a less frequent maintenance cadence than most peer biologics. Eligibility typically requires a documented eosinophilic phenotype (blood eosinophils ≥300 cells/µL historically, though FDA labeling does not formally cap eligibility at a threshold), recurrent exacerbations on high-dose ICS/LABA, and a pulmonologist's assessment of fit versus other severe-asthma biologics.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Fasenra legally importable into Saudi Arabia?
Yes, through the Saudi Food and Drug Authority (SFDA) named-patient / personal-use import framework. The pathway permits a Saudi Arabia-licensed physician to request import of a medicine when (a) the medicine is approved by a recognised reference authority such as the US FDA or EMA, (b) no clinically equivalent locally available option meets the patient's needs, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented end to end. Fasenra is registered in Saudi Arabia, so named-patient import is typically used when a specific presentation (autoinjector vs prefilled syringe) is preferred, when timing matters, or when cross-border DSCSA documentation is required for other reasons.
How the pathway works, step by step
- Consultation with your treating pulmonologist or allergist. Severe-asthma diagnosis, eosinophil-phenotype confirmation, exacerbation history, and prior controller regimen.
- Phenotype workup. Blood eosinophil count, FeNO, IgE and allergen panel to confirm eosinophilic phenotype fit.
- SFDA named-patient application. Your physician, the hospital pharmacy, or the patient under prescription files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Fasenra from authorised distribution under DSCSA.
- Cold-chain shipment. Fasenra ships under validated 2-8 °C conditions with temperature logging and chain-of-custody documentation.
- Arrival and administration. The first three doses are administered every four weeks under clinician supervision or, after training, at home; from dose four, dosing is every eight weeks.
What documentation your physician needs
- Clinical rationale letter confirming severe eosinophilic asthma, exacerbation history, prior controller regimen, and Fasenra as the indicated biologic
- Verification of Saudi Arabia medical licence (DHA / DOH / SFDA as applicable)
- Blood eosinophil count and other phenotype data
- Spirometry results (FEV1, reversibility)
- Planned dosing schedule and follow-up cadence
- Patient identifier and residential address for import clearance
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for anti-IL-5-class biologic named-patient imports.
Typical costs and indicative timing
Fasenra's US cash-pay drug-only reference range in 2026 sits at roughly USD 5,500-7,000 per 30 mg SC autoinjector dose. International cold-chain logistics, SFDA documentation handling, customs clearance, and concierge coordination are quoted separately. Reserve Meds issues a full transparent delivered quote at intake so your family sees one landed number before committing. Indicative range.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete SFDA application is in hand. Maintenance doses ship on the every-eight-week cadence after the loading phase.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Fasenra specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from authorised channels.
- Documentation. Regulatory package for your physician and SFDA review, including anti-IL-5R phenotype templates.
- Logistics. Validated 2-8 °C cold-chain shipment with temperature logging.
- Concierge case lead. A named point of contact coordinating the loading phase and every-eight-week maintenance.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating pulmonologist.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient / personal-use framework with appropriate documentation. See our trust and compliance page for our methodology.
How does Fasenra differ from Nucala? Both target IL-5 biology in severe eosinophilic asthma, but Fasenra binds the IL-5 receptor on eosinophils (directly depleting them) while Nucala binds the IL-5 ligand (preventing receptor activation). Fasenra's maintenance cadence is every eight weeks after loading; Nucala is every four weeks. Your pulmonologist chooses based on phenotype, response to prior biologics, and cadence preference.
Can I self-inject at home? Fasenra is available as a single-use autoinjector; self-administration is supported after clinician training. Your physician decides when home dosing begins.
Is Fasenra suitable for allergic asthma without eosinophilia? Fasenra is targeted at eosinophilic phenotype. Allergic asthma without eosinophilia is typically better matched with Xolair (anti-IgE) or Tezspire (anti-TSLP); your pulmonologist assesses fit.
Will private insurance cover this? Cash-pay is the default. Some Saudi Arabia private insurers consider named-patient imports case by case; we supply documentation for your submission but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Fasenra (benralizumab) in Saudi Arabia, 2026
Fasenra (benralizumab) is approved by the US Food and Drug Administration for the labelled indication of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Fasenra (benralizumab) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Fasenra (benralizumab) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Fasenra (benralizumab) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For anti-IL-5 receptor alpha monoclonal antibody therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Fasenra (benralizumab) reflects the US wholesale acquisition cost published by the manufacturer (AstraZeneca) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Fasenra (benralizumab) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Fasenra (benralizumab) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Fasenra (benralizumab): the labelled indication is severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome. The anti-IL-5 receptor alpha monoclonal antibody mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is Global Initiative for Asthma (GINA) and the European Respiratory Society / American Thoracic Society guidelines at ginasthma.org/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Fasenra (benralizumab) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Fasenra (benralizumab); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Fasenra (benralizumab) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Fasenra (benralizumab) remains severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (see the current FDA approval record at accessdata.fda.gov). AstraZeneca continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The Global Initiative for Asthma (GINA) and the European Respiratory Society / American Thoracic Society guidelines guidance at ginasthma.org/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.